Bajaj Healthcare informs about disclosure

30 Jan 2025 Evaluate

Bajaj Healthcare has informed that the company has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule. The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market. The press release in this regard, being issued by the Company is submitted. Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 & the Company’s code of Internal Procedures and Conduct for Regulating, monitoring & reporting of trading in securities, the Trading window for dealing in securities of the company shall continue to remain closed for all the Directors and Designated Employees in terms of its earlier disclosure dated 27th December 2024.

The above information is a part of company’s filings submitted to BSE.

Bajaj Healthcare Share Price

670.35 -0.95 (-0.14%)
02-Apr-2025 12:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.25
Dr. Reddys Lab 1149.75
Cipla 1452.70
Lupin 2009.40
Zydus Lifesciences 891.25
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...